China Innovation Pharmaceutical Expressing Film Force, the deepening layout of the cornerstone pharmaceutical industry to accurately treat commercialization and then speed up

In the past two years, thanks to the strong support of national policies, Chinese biopharmaceutical companies have been approved to be listed one after another, including cornerstone pharmaceuticals, Nuo Chengjianhua, Yasheng Pharmaceutical and other innovative pharmaceutical companies have achieved zero breakthroughs. In this regard, Dr. Zhou You, general manager and head of the business department of the Greater China Pharmaceutical Greater China, pointed out that this is due to the external environment and a comprehensive manifestation of the internal power of the enterprise. Tang Yanzhang, a partner of Qiming Venture Capital, also pointed out that the review time has been significantly shortened and talents have laid a very good foundation for the rise of the entire Chinese innovation medicine.

Just recently, the Gramopa Pharmaceutical Tuoshuo® was officially listed in China. It took only 6 months from the application for the application of the new drug listing to the official approval, which once again reflected the rapid development of the industry. Takuwa® is a oral targeted inhibitor for IDH1 mutant enzymes. It has been approved by the China National Drug Administration to treat adult recurrence or refractory acute myeloid leukemia (R/ R AML) Patients.

As of now, 4 new drugs have been approved for listing in 6 years. While the innovative drugs are continuously approved, innovative pharmaceutical companies such as the cornerstone pharmaceutical industry also actively set up commercial teams and strengthen external commercial cooperation to continuously speed up the commercialization layout. Zhou You pointed out that it is currently actively accelerating the implementation of Tuoshuo® in the country and has been included in 5 cities Huimin Insurance and commercial health insurance. Cornerstone Pharmaceuticals will continue to work in commercial cooperation and work with more partners to work in hand. Commercial innovation, further enhance the availability and payment of cornerstone pharmaceutical innovation drugs, and benefit more patients.

At the same time, Zhouyou particularly emphasized that innovative pharmaceutical companies need to respect the characteristics of accurate target products in the commercial layout and carry out targeted layout. Through the National Medical Insurance Bureau, insurance company, pharmaceutical companies and other parties, they will jointly explore the multi -level guarantee payment system, and will also promote the availability and commercialization of precision therapeutic drugs including the cornerstone pharmaceutical industry.

6 years of the four new drugs to go public in depth layout accurate treatment

"In traditional sense, AML is considered to have a certain technical threshold and complicated disease in the blood field. Often, the number of large centers need to be carried out. Since the listing of Takuwo®, we have also found some ordinary tertiary hospital doctors. AML also started. "Zhou You pointed out.

In order to quickly help the majority of hospitals improve the diagnosis, the cornerstone pharmaceutical industry has signed a strategic cooperation memorandum with the test of the head enterprise Kangsheng Ling Global with the technical advantages and regional coverage advantages in the field of blood testing in July. Education for inspection concepts.

Regarding the cooperation with Kang Sheng Global, Dr. Jiang Ningjun, CEO of Cornerstone Pharmaceuticals, said: "Precision diagnosis is the cornerstone of precision treatment. The availability and standardization of genetic testing of AML patients still need to be improved."

In fact, the cornerstone pharmaceutical industry has also made a series of layouts around precision treatment. Compared with the first half of 2021, the accurate therapeutic drugs of the cornerstone pharmaceutical industry have increased from 7 guidelines to more than 10 guidelines. At the same time, the progress of new drugs has continued to accelerate. At present, the cornerstone pharmaceutical industry has obtained 4 new drugs and 9 NDA (new drug listing application) approval. In addition to the above mentioned Topshwo® Jihua® and Taijihua® have also realized commercialization across the country, and their ability to make self -hematopoietic has increased significantly.

In October 2017, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging Pharmaceutical Medical Device Innovation", including solving the accumulation of drug registration applications and shortening the review cycle. Since then, in July 2020, the State Drug Administration issued the "Breakthrough Treatment Pharmaceutical Review Procedures (Trial)", "Pharmaceuticals Evaluation Application Application Approval Procedures (Trial)", "Pharmaceutical Listing License Priority The three documents of the review and approval work procedure (trial) put forward further requirements for the pharmaceutical approval procedure.

Cornerstone Pharmaceuticals can realize the rapid listing of multiple innovative drugs, and it is also inseparable from its increasing R & D investment in recent years. Cornerstone Pharmaceutical's annual research and development investment is about 1.3 billion yuan. With its own clinical R & D capabilities and continuous research and development resources, the Core Stone Pharmaceuticals has expanded more in the product field and promoted pipeline 2.0 to develop forward. At the same time, in order to further upgrade the internal research and development and innovation capabilities, Cornerstone Pharmaceuticals launched the construction of global R & D headquarters and industrialized production bases. Among them, the global R & D headquarters facilities occupy about 16,000 square meters of R & D and office space, which is 6 times that of existing facilities. The investment operations of the Global R & D headquarters of Cornerstone Pharmaceuticals will further strengthen internal research and development capabilities.

Speed ​​the pace of commercialization

While the new drug is continuously approved to be listed, the commercialization of cornerstone pharmaceuticals is also accelerating. In addition to actively promoting market sales coverage, the cornerstone pharmaceutical industry also sells self -developed product equity through License Out to obtain high returns. At present, the cornerstone pharmaceuticals are only as follows of Schurli Mipoly (PD-L1), CS1003 (PD-1), and CS1002 (Anti-CTLA-4 monoclonal) and other self-developed products. income.

Cornerstone Pharmaceutical and Global R & D headquarters have also begun trial operation. With the decline in production costs and the improvement of closed -loop supply capacity in the future, the commercial value of cornerstone pharmaceutical products will be further released.

Compared with traditional pharmaceutical companies, from the perspective of Zhouyou, the business model of innovative bioplasses can be summarized with 4 keywords: efficiency, accuracy, innovation, and ecology. In terms of efficiency, innovative bioplasses must achieve a higher and faster result compared with traditional pharmaceutical companies in a short period of time. Zhou You believes that at any time, regardless of whether the capital investment is abundant or tightened, the enterprises of the long -term foundation must be improved. Whether it is a tangible, quantified productivity, or an intangible decision -making speed.

"In the past few years, the concept of winning in scale has gradually gone. For innovative bioplasses, prudent expansion and efficiency have become consensus in the industry." Zhou You pointed out.

In terms of precision, Zhou You believes that many innovative bioplasses are concentrated in the field of tumor fields, or the precision medicine field of tumors, and need to be deployed in advance to meet the needs of customers and provide accurate therapy to patients. In the layout of commercial promotion activities, there must be a choice.

In terms of ecology, precision medicine is still a relatively cutting -edge field, full of complex problems, such as disease diagnosis, payment system, and patient support system. In the ecosystem, grow with ecological partners.

Another important keyword innovation, simple processes cooperate with efficient decisions, becoming the most effective soil for cultivating innovation. "The precise treatment of tumor patients cannot be tried and error. However, in terms of commercial marketing and innovation of tumor drugs, the concept of Agile Innovation (agile innovation) is used to quickly try and error, pilot and expand, and form the advantages of mechanisms to improve the speed. Give us a lot of advantages. "

Zhou You said that the commercialization of the cornerstone pharmaceutical industry has always followed the commercialization of 4 points above. Taking efficiency as an example, this year and next, the important point of the cornerstone commercialization team pays attention to improve productivity, including the quantitative angle of productivity, which also includes non -fixed quantitative quantitative quantitative quantitative quantitative quantitative quantitative quantitative volume For example, project effectiveness improvement, etc.

So far, the listing of four indications of the three precision target products shows the speed of commercialization of the cornerstone pharmaceutical industry. These two years are the critical stage of the cornerstone pharmaceutical transformation from Biotech to BioPharma. The diagnosis of related diseases, strengthening academic leadership, strengthening availability and payable, and providing high -quality patient education and services to make a good commercial layout.

On the one hand, the Cornerstone Pharmaceuticals built nearly 300 commercial teams, and on the other hand, through industry cooperation, it actively expanded commercialization channels through multi -party cooperation with Sinopharm Holdings, Magnesium Health Health, Beijing Yuanxin Technology and other parties.

It is understood that the cornerstone pharmaceutical industry forms a joint force in the region, and the highly believes between various functions. Medical, marketing, and sales can be information symmetry locally, respond to customer needs efficiently, reduce headquarters decision -making time, thereby improving efficiency.

Last mile

Zhouyou particularly emphasized that innovative pharmaceutical companies need to respect the characteristics of accurate target products in the commercial layout, and carry out targeted layouts, such as: from the perspective of clinical academics, help doctors establish "precise targets, target targets" faster Concept, highlight the differentiated advantages of the product, and use real cases to help doctors establish this concept. If there is a learning association led by the Association not long ago, the "Rare Target Cases of Lung -Cancer RET" has been released, and the curative effect is the most convincing.

"In the past, there was no choice. Doctors may tend to use multiple target inhibitors for patients. Now there are options. The doctor’s treatment goals are also improving, pursuing the maximum benefits of each individual patient. In the struggle, the "sniper rifle" era with the "scattered shotgun" era to 'clear goals and exact effects'. "Zhou You pointed out.

"From the perspective of target testing, for many second echelon hospitals, the inspection rate still has room for improvement. To this end, we are also promoting clinicians and pathologists, and laboratories, and more MDTs. Dialogue. In the past, there were some targets, even if they were detected, there were no specific treatment. There was no meaningful test for clinical decision -making, and clinicians may tend to do not consider it, but now it is detected. Change, there is medicine to cure, which will also promote the improvement of clinical examination concepts. "Zhou You said.

According to reports, the cornerstone pharmaceutical industry will carry out pathology and clinical multidisciplinary academic exchanges, cooperate with the Pathological Quality Control Center to help improve the accuracy of diagnosis, and jointly build more than 20 regional tumor diagnosis and treatment bases with ecological partners; Purch A® and Taijihua® have entered more than 60 city Huimin insurance or commercial insurance, and will continue to expand to more than 80 items this year.

The reason why patients education and services are used as one of our four strategic pillars, and the logic behind this explains that the logic behind this is: pay attention to the convenience of knowledge, so that the voice of the patient's voice in the closed loop of the diagnosis and treatment is getting more and more and more and more important.

"The importance of patient education has evolved from the field of general medicine (20 years ago, the affected grassroots at the grassroots level of diabetes high blood pressure) to the field of special medicine (10-15 years ago, the specialty field began to appear in the field of specialty), and now it has also evolved In the field of precision targeted therapy, the large media of the public media/professional media/doctors have reduced the cost of knowledge obtaining knowledge, and developed the habit of seeking the patient's initiative to seek the 'Second Opinion Online'. In addition, the patient's requirements for the quality of service quality Improving the hardware and software environment of the diagnosis and treatment of offline third -level hospitals has improved, and patients' requirements for online services have also been improved. From the history of industry development, companies that truly care about patients to implement their long -term development can achieve long -term development. "Zhou You said Cornerstone Pharmaceuticals provides patients with disease -related one -stop knowledge and online and offline affected education classrooms through online platforms such as life and watching with the foundation. For innovative medicines to enter the hospital, the last mile problem is more optimistic about the general trend. "For the drugs that have entered the state -discourse medical insurance directory, the state has been promoting. For example, the situation of entering the hospital after understanding the negotiations of the country's drug negotiations; some places have proposed the goal of the national conversation drugs in the Three Hospital '" It has also been purchased and reimbursed for some national talks with drugs in dual -channel DTP pharmacies. Looking back at the past few years, evolution is still relatively fast. "Zhou You said.

The drug that failed to include the medical insurance directory for the time being, and Zhou You pointed out that its changes have also developed rapidly. At present, the changes in the drug circulation industry are also very fast. Through Internet hospitals, online prescriptions and offline delivery, etc., the acquisition of drugs is not difficult. Pharmacy receives medicine and receive insurance payment.

The essence of the last mile of innovative drugs is actually a problem that can be solved at the same time of availability and payment. The National Medical Insurance Bureau, insurance company and pharmaceutical companies are explored together to accelerate the release of more solutions. This will actually promote the availability and commercialization of innovative pharmaceutical companies including the cornerstone pharmaceutical industry.

- END -